Previous 10 | Next 10 |
Ampio Pharmaceuticals ([[AMPE]]) announces results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis, a condition that causes inflammation of the kidney.The aim of ...
Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis Laboratory results suggest Ampion's suitability for addressing kidney diseases and provides further evidence it is a platform biologic for treatment of inflammatory and ...
Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress The company's findings will be showcased to over 400 clinicians, respiratory health and critical care professionals, aerosol scientists, engineers, product d...
Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap Conference PR Newswire ENGLEWOOD, Colo. , March 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immu...
Shares of Ampio Pharmaceuticals (AMPE) are up 7.5% to $1.95 in morning trading after the company reported preliminary positive phase 1 results for AP-014, an inhaled treatment for respiratory distress in patients with COVID-19.AP-014 is testing an inhaled version of the company's Am...
Ampio Pharmaceuticals ([[AMPE]] +4.7%) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.The company also outlined its progress toward initiating a Phase I clinical tria...
Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress Also provides updates on (i) forthcoming Phase I clinical trial utilizing inhaled Ampion to treat "long hauler" COVID-19 symptoms and (ii) research into indications in kidney...
This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...
Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021 PR Newswire ENGLEWOOD, Colo. , March 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the ad...
Shares of Ampio Pharmaceuticals (NYSEMKT: AMPE) were jumping 8.4% as of 11:51 a.m. EST on Thursday. The nice gain came after the company provided its fourth-quarter update following the market close on Wednesday. Investors probably didn't care all that much about Ampio's Q4 resu...
News, Short Squeeze, Breakout and More Instantly...
Ampio Pharmaceuticals Inc. Company Name:
AMPE Stock Symbol:
OTCMKTS Market:
Ampio Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 94.4% to $0.07 on volume of 92,836,985 shares AGBA Group Holding Limited (AGBA) rose 46.1% to $1.505 on volume of 55,502,222 shares PROSHARES TRUST (SQQQ) rose 1.2% to $12.2099 on volume of 25,933,897 shares...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 7.2% to $0.04 on volume of 426,309,096 shares PROSHARES TRUST (SQQQ) rose 1.8% to $12.07 on volume of 171,048,374 shares AGBA Group Holding Limited (AGBA) rose 157.5% to $1.03 on volume of 121,894,6...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 73.2% to $0.0646 on volume of 191,555,690 shares AGBA Group Holding Limited (AGBA) rose 245.0% to $1.38 on volume of 41,065,125 shares TIAN RUIXIANG Holdings Ltd (TIRX) rose 135.2% to $1.14 on volum...